Results Summary of basic information of existing GLP-1RA in China As of December 2023, there were 9 drugs in the GLP-1RA class approved for the treatment of T2DM in China, including Semaglutide injection, Liraglutide injection, Dulaglutide injection, Polyethylene glycol loxenatide injection, Insulin degludec and liraglutide injection, Exenatide injection, Benaglutide injection, Exenatide microsphees for injection, and Lixisenatide injection [21, 22]
The authors reported that the metabolite Ac-LKKTE showed greater wound-closure activity in their fibroblast assay than the parent fragment
The exact dose depends on each patients response, lifestyle habits, and overall health
Lyophilised (freeze-dried) peptide compounds used in clinical trials must be reconstituted with a sterile diluent before administration